Sponsored · Market Discovery Content
Wall Street Wire
Sponsored market-discovery coverage of emerging public companies. Every Wall Street Wire piece is paid content and carries a full disclaimer.
Wall Street Wire pieces are paid market-discovery content published on behalf of the companies covered. They are not investment advice. Each article carries its full disclaimer at the end.
Wall Street Wire
Entera Bio CEO Adds to Stake as FDA Qualifies New Osteoporosis Endpoint
Dec 30, 2025
One of the Most Neglected Medical Markets Finally Has a New Contender – and It’s a Microcap Few Are Watching
Could Nasal Powders Be the Next Revolution in Emergency Medicine?
Elite Investment Bank Engaged by DarioHealth to Find Strategic Buyers as Healthcare Cost Crisis Drives Urgent Demand
Israeli Cannabis Leader InterCure Snatches Up Premium Tech Company in Perfect Pre-Rescheduling Play
FDA Accepts COYA 302 Application as Dr. Reddy’s Expands Innovation Portfolio
The Device That Acts Like a Drug: Alpha Tau’s Secret Weapon in Cancer Care (NASDAQ: DRTS)
DarioHealth Q2 Results May Present Compelling Long-Term Story Despite Near-Term Revenue Headwinds
Meet Entera Bio: The $85M Company That Could Solve Big Pharma’s Oral GLP-1 Problem
Laidlaw Analyst Doubles Down on Nuvectis Citing NXP900 as True Value Driver; Reiterates $19 Price Target
Lithium Market’s Razor-Thin Balance Exposed: Why NOA Lithium Brines Inc. (TSXV: NOAL) Benefits from Supply Chain Fragility
NXP900: The Breakthrough Drug That Could Transform Nuvectis Pharma Into a Multi-Billion Dollar Biotech Giant
The $100 Billion Bet: Why Palatin Technologies Could Be 2025’s Most Overlooked Biotech Opportunity
BiomX Advances with Phase 2b Trial Initiation, Wall Street Analyst Reaffirms $15 Price Target
Roth Capital Analyst Reiterates $9 Price Target for PolyPid Following GLP-1 News
Tiny Biotech with 500% Upside Potential Targets Cancer’s Most Deadly Mutation (NASDAQ: SLXN)
This $13M Biotech Has $40M in Pentagon Funding – Here’s Why BiomX Could Be Biotech’s Best-Kept Secret
Biotech Insider Loads Up on Nuvectis Pharma — Is This the Next Big BioPharma Play?
Actelis Networks Strengthens Federal Position with 30-Year Defense Veteran Amid Market Expansion (NASDAQ: ASNS)
Elbit’s Secret Weapon Partner – Israeli MicroCap Drone firm Duke Robotics’ Rises Fast Amidst Israeli-Iran Conflict (OTCQB: DUKR)
